AKT1 and melanoma: Since both Axl and PI3K/AKT pathways are involved in the development of melanoma with other gene mutations, the combination of Axl inhibitors and PI3K/AKT pathway inhibitors can be considered for the treatment of melanoma with other gene mutations in subsequent studies.